Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 188

3.

Bioequivalence of oxycodone hydrochoride extended release tablets to marketed reference products OxyContin® in Canada and US.

Gosai P, Ducharme MP, Godfrey AR, Freeman JC, Monif T, Kumar KS, Kumar S, Mudnaik R, Katikaneni P.

Int J Clin Pharmacol Ther. 2013 Nov;51(11):895-907. doi: 10.5414/CP201764.

PMID:
23673291
4.

Effect of food on the pharmacokinetics of oxycodone and naltrexone from ALO-02, an extended release formulation of oxycodone with sequestered naltrexone.

Gandelman K, Lamson M, Salageanu J, Bramson C, Matschke K, Malhotra B.

Clin Pharmacol Drug Dev. 2015 Sep;4(5):370-6. doi: 10.1002/cpdd.177. Epub 2015 Jan 22.

PMID:
27137146
5.

Assessing subjective and physiologic effects following intranasal administration of a new formulation of immediate release oxycodone HCl (Oxecta™) tablets in nondependent recreational opioid users.

Schoedel KA, Rolleri RL, Faulknor JY, Pixton GC, Chen N, Bass A, Sommerville KW, Sellers E.

J Opioid Manag. 2012 Sep-Oct;8(5):315-27. doi: 10.5055/jom.2012.0131.

PMID:
23247908
6.

Single- and multiple-dose pharmacokinetic evaluation of oxycodone and naloxone in an opioid agonist/antagonist prolonged-release combination in healthy adult volunteers.

Smith K, Hopp M, Mundin G, Leyendecker P, Bailey P, Grothe B, Uhl R, Reimer K.

Clin Ther. 2008 Nov;30(11):2051-68. doi: 10.1016/j.clinthera.2008.11.008.

PMID:
19108793
7.

Intranasal abuse potential of an abuse-deterrent oxycodone formulation compared to oxycodone immediate release and placebo in nondependent, recreational opioid users.

Setnik B, Schoedel K, Bartlett C, Dick C, Hakim N, Geoffroy P.

J Opioid Manag. 2017 Nov/Dec;13(6):449-464. doi: 10.5055/jom.2017.0421.

PMID:
29308591
8.

Effects of ethanol on the pharmacokinetics of extended-release oxycodone with sequestered naltrexone (ALO-02).

Malhotra BK, Matschke K, Wang Q, Bramson C, Salageanu J.

Clin Drug Investig. 2015 Apr;35(4):267-74. doi: 10.1007/s40261-015-0278-6.

PMID:
25724154
9.

Pharmacokinetic properties of combination oxycodone plus racemic ibuprofen: two randomized, open-label, crossover studies in healthy adult volunteers.

Kapil R, Nolting A, Roy P, Fiske W, Benedek I, Abramowitz W.

Clin Ther. 2004 Dec;26(12):2015-25.

PMID:
15823765
10.

Bioavailability of oxycodone after administration of a new prolonged-release once-daily tablet formulation in healthy subjects, in comparison to an established twice-daily tablet
.

Scheidel B, Maritz MA, Gschwind YJ, Steigerwald K, Guth V, Kovacs P, Rey H.

Int J Clin Pharmacol Ther. 2017 Nov;55(11):881-890. doi: 10.5414/CP203005.

11.

Opioid formulations designed to resist/deter abuse.

Raffa RB, Pergolizzi JV Jr.

Drugs. 2010 Sep 10;70(13):1657-75. doi: 10.2165/11537940-000000000-00000. Review.

PMID:
20731474
12.

Pharmacokinetics and bioavailability of oxycodone and acetaminophen following single-dose administration of MNK-795, a dual-layer biphasic IR/ER combination formulation, under fed and fasted conditions.

Devarakonda K, Morton T, Margulis R, Giuliani M, Barrett T.

Drug Des Devel Ther. 2014 Aug 19;8:1125-34. doi: 10.2147/DDDT.S64261. eCollection 2014.

13.

Comparison of the pharmacokinetics of oxycodone administered in three Percocet formulations.

Gammaitoni AR, Davis MW.

J Clin Pharmacol. 2002 Feb;42(2):192-7.

PMID:
11831542
14.

Characterization and validation of a pharmacokinetic model for controlled-release oxycodone.

Mandema JW, Kaiko RF, Oshlack B, Reder RF, Stanski DR.

Br J Clin Pharmacol. 1996 Dec;42(6):747-56.

16.
17.

Comparing the Effect of Tampering on the Oral Pharmacokinetic Profiles of Two Extended-Release Oxycodone Formulations with Abuse-Deterrent Properties.

Gudin J, Levy-Cooperman N, Kopecky EA, Fleming AB.

Pain Med. 2015 Nov;16(11):2142-51. doi: 10.1111/pme.12834. Epub 2015 Jun 22.

PMID:
26108255
18.

Impact of physical manipulation on in vitro and in vivo release profiles of oxycodone DETERx®: an extended-release, abuse-deterrent formulation.

Kopecky EA, Fleming AB, Noonan PK, Varanasi RK, Grima M, Saim S, Mayock SP.

J Opioid Manag. 2014 Jul-Aug;10(4):233-46. doi: 10.5055/jom.2014.0211.

PMID:
25162603
19.

Relative bioavailability of a newly developed 5-mg levomethadone hydrochloride IR tablet (L-Polamidon® 5 mg tablets) in comparison with the 5-mg levomethadone hydrochloride oral solution (L-Polamidon® solution for substitution) as reference product.

Blume HH, Wedemeyer RS, Donath F, Roscher K, Elvert G, Wagner D, Bley O, Vuia A, Todorova-Sanjari M, Villalobos R, Schug B.

Int J Clin Pharmacol Ther. 2015 Apr;53(4):335-44. doi: 10.5414/CP202180.

PMID:
25669614
20.

Comparative bioequivalence studies of tramadol hydrochloride sustained-release 200 mg tablets.

Khandave SS, Sawant SV, Joshi SS, Bansal YK, Kadam SS.

Drug Des Devel Ther. 2010 Nov 25;4:367-74. doi: 10.2147/DDDT.S15133.

Supplemental Content

Support Center